Ovarian Function Suppression: Is it the Right Time to Jump the Gun?
Sunny Jandyal, Jyoti Bajpai*
DM Medical Oncologist, Tata Memorial Cancer Center, Mumbai, India
- *Corresponding Author:
- Jyoti Bajpai
DM Medical Oncologist
Tata Memorial Cancer Center
E-mail: [email protected]
Received date: October 24, 2016; Accepted date: December 09, 2016; Published date: December 16, 2016
Citation: Jandyal S, Bajpai J (2016) Ovarian Function Suppression: Is it the Right Time to Jump the Gun? J Integr Oncol 5:183. doi: 10.4172/2329-6771.1000183
Copyright: © 2016 Bajpai J, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Ovarian function suppression (OFS) an old endocrine therapy has been tested in premenopausal women with early breast cancer (EBC) but not widely accepted in modern practice. The question is re-addressed in recent big trials, however the big dilemma doesn't resolved. This perspective touch upon the ancient as well as current evidence of OFS in these young early breast cancer women and try to enlighten the readers further on this controversial topic wherein there is lots of light but little illumination.